Creative Commons License

Except where otherwise noted, the content provided on this site is licensed under a Creative Commons Attribution-NoDerivs 2.5 License.

News Detail

E-mail this page Email a link to this Page   

Symyx Technologies Enters into Discovery Tools and Renaissance Software Licensing Agreement with Pfizer

SANTA CLARA, Calif., Jan 5, 2004 (BUSINESS WIRE) -- Symyx Technologies, Inc. (Nasdaq:SMMX) announced today that it has entered into an agreement with Pfizer Inc (NYSE:PFE) to deliver a Symyx Discovery Tools(R) Polymorph/Pre-Formulations Workflow system and to license applications of Symyx Renaissance Software(R) for use in five Pfizer research sites.

The Discovery Tools Polymorph/Pre-Formulations Workflow is a high throughput integrated workflow designed to rapidly identify optimal crystalline salt and polymorphic forms of drug candidates. Selection of the correct form of the drug for clinical trials is an important part of drug development. Molecules often crystallize in more than one polymorphic form depending on the specific crystallization and purification conditions used in manufacturing. Each polymorph can have a unique set of physiochemical properties such as melting point, solubility, stability, and bioavailability. Early selection of the crystalline polymorph with the best overall properties is critically important to pharmaceutical companies to promote the best candidate to clinical trials and to avoid the emergence of new polymorphs later in the drug development process.

Through this agreement, Pfizer becomes the first pharmaceutical company to license Renaissance Software for use independent of a Discovery Tools system. Renaissance Software is a highly integrated, proprietary suite of software designed to facilitate the process of designing, executing, and evaluating materials research. The Renaissance Software can be applied to enhance the pre-clinical development process, including Symyx Library Studio(R) for designing and specifying libraries, Symyx PolyView(R) for querying and analysis of data and trends, Symyx Spectra Studio(R) for spectral data clustering and secondary analysis, and the Symyx Renaissance Application Server (RAS) to provide a world-wide shared environment for data storage.

Symyx expects to complete delivery of the Polymorph/Pre-Formulations Workflow and to begin the software installations in the first quarter, 2004.

Symyx develops and applies high-throughput experimentation to the discovery of innovative materials for the chemical, life science, electronics, consumer goods, and automotive industries. Symyx works with companies seeking to transform their search for better products and processes through research collaborations, Discovery Tools(R) sales, and license of materials, intellectual property, and software. Information about Symyx, including reports and other information filed by the Company with the Securities and Exchange Commission, is available at

Certain statements in this press release are forward-looking and involve risks and uncertainties. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "forecast," "estimated," and "potential," among others. These forward-looking statements are based on Symyx's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Symyx notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Symyx's businesses include but are not limited to (1) market acceptance of Symyx's products and services; (2) uncertainties relating to the pace, quality or number of discoveries of new materials; (3) the dependence on collaborators to continue relationships and to successfully commercialize products; (4) uncertainties of patent protection and litigation; (5) future growth strategy; (6) general economic conditions in the United States and in major European and Asian markets; (7) exposure to risks associated with export sales and operations; (8) natural disasters, power failures and other disasters; (9) and other factors that might be described from time to time in Symyx's filings with the Securities and Exchange Commission, including our Form 10-K annual report for our most recently completed fiscal year and any subsequently filed Form 10-Q quarterly reports.

SOURCE: Symyx Technologies, Inc.

Symyx Technologies, Inc.
Jeryl L. Hilleman, 408-773-4000

Posted by: limsfinder on Jan 09,04| Profile| Pharmaceutical


signupor loginto post a comment.

Enter New Comments: